MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

511.47 -4.17

Buy Sell

Overview

Share price change

24h

Current

Min

504.13

Max

532.52

Key metrics
By Trading Economics
Income	56M -59M
Sales	34M 321M
Profit margin	-18.243
Employees	915
EBITDA	56M -50M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+32.03% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1.7B 12B
Previous open	515.64
Previous close	511.47

News Sentiment

By Acuity

34%

66%

95 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 kwi 2026, 17:26 UTC

Major News Events

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7 kwi 2026, 23:55 UTC

Market Talk

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7 kwi 2026, 23:47 UTC

Market Talk

Major News Events

Market Talk Roundup: Latest on U.S. Politics

7 kwi 2026, 23:47 UTC

Market Talk

Major News Events

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7 kwi 2026, 23:44 UTC

Market Talk

Major News Events

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7 kwi 2026, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

7 kwi 2026, 23:42 UTC

Market Talk

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7 kwi 2026, 23:37 UTC

Market Talk

Major News Events

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7 kwi 2026, 23:15 UTC

Market Talk

Major News Events

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7 kwi 2026, 23:04 UTC

Major News Events

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7 kwi 2026, 23:04 UTC

Major News Events

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7 kwi 2026, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 kwi 2026, 23:03 UTC

Market Talk

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7 kwi 2026, 23:01 UTC

Major News Events

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7 kwi 2026, 22:58 UTC

Major News Events

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7 kwi 2026, 21:56 UTC

Acquisitions, Mergers, Takeovers

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

7 kwi 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 kwi 2026, 19:45 UTC

Market Talk

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7 kwi 2026, 19:17 UTC

Major News Events

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7 kwi 2026, 19:16 UTC

Market Talk

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7 kwi 2026, 19:07 UTC

Market Talk

Global Energy Roundup: Market Talk

7 kwi 2026, 19:07 UTC

Market Talk

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7 kwi 2026, 18:41 UTC

Acquisitions, Mergers, Takeovers

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7 kwi 2026, 18:40 UTC

Acquisitions, Mergers, Takeovers

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7 kwi 2026, 18:39 UTC

Acquisitions, Mergers, Takeovers

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7 kwi 2026, 18:24 UTC

Major News Events

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7 kwi 2026, 17:08 UTC

Market Talk

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7 kwi 2026, 16:21 UTC

Major News Events

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7 kwi 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

32.03% upside

12 Months Forecast

Average 704.88 USD 32.03%

High 964 USD

Low 529 USD

Based on 9 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

95 / 349 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.